Clinical Trial Update: 12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of flexible dosing of CP-526,555 versus placebo for smoking cessation over 12 weeks.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• CP-526,555

Snippet

Sponsor: Pfizer | Conditions: Smoking Cessation | Phase 2 | Status: COMPLETED